JAK1 and Alzheimer disease: Other topical JAC inhibitors, which are under investigation for the treatment of AD comprise Cerdulatinib (DMVT-502, dual JAK and spleen tyrosine kinase inhibitor), Brepocitinib (JAK1 and TYK2 inhibitor), ATI-502 (JAK1/3 inhibitor) and SHR0302 (JAK1 inhibitor) [66,67,68,69].